Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in retinal bipolar cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 205 | 0.82 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10279
Sealed predictions
- NRXN3 in dopamine neurons, braak+0.11 (p 0.770) → +0.21 (p 0.586)receipt 10288
Swarm cases
receipt 10288: NRXN3 in dopamine neurons, braak
- power
- full sample +0.16 (p 0.521, n 18), 95% CI -0.33 to +0.58. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.22 (p 0.384, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.22 (p 0.389, n 18). could be the mix.
- skeptic
- leave-one-out range +0.09 to +0.33, sign flips 0; without severely affected donors +0.16 (p 0.521, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NRXN3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts